Post-surgical ctDNA as a prognostic biomarker for relapse of resected cholangiocarcinoma

BACKGROUND: ctDNA is increasingly used to detect minimal residual disease, however, its sensitivity varies by tumor type. Its utility in CCA remains incompletely defined. METHODS: In this single-institution retrospective study, we evaluated ctDNA using a commercial tumor-informed assay (Signatera), compared with CA19-9, for predicting relapse after surgical resection during postoperative (<90 days) and surveillance (≥90 days) windows. We assessed associations between ctDNA status and clinical features, including resection pathology and sites of radiographic relapse. RESULTS: Of 48 patients with CCA who underwent resection between 2020-2025, 26 (54.2%) experienced relapse (median follow-up 18.3 months). ctDNA positivity during both postoperative and surveillance windows was associated with worse median disease-free survival, whereas CA19-9 was not. During the postoperative window, ctDNA sensitivity was 41.7% and specificity was 85.7% for predicting disease relapse any time post-resection. During the surveillance window, sensitivity was 60.0% and specificity was 90.9%. Landmark analysis for relapse at 1-year for ctDNA collected prior to 90 days had a sensitivity of 83.3% and specificity of 90.0%. Among patients with detectable ctDNA who subsequently developed radiographic relapse, median lead time from first ctDNA positivity to relapse was 34 days (IQR 26-132 days), with a maximum lead time of 292 days. ctDNA performance was higher among patients without perineural or lymphovascular invasion and was most frequently positive in those who developed extrahepatic metastases (n = 10/13, 76.9%). CONCLUSIONS: ctDNA is a specific prognostic biomarker that outperforms CA19-9 for predicting relapse after CCA. However, negative ctDNA results should be interpreted cautiously given modest assay sensitivity.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-11-18
DOI
https://doi.org/10.1093/oncolo/oyag455
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-surgical ctDNA as a prognostic biomarker for relapse of resected cholangiocarcinoma

Marco Dal Molin, Dung Thi Le, Matthew Z. Guo, Mari Nakazawa et al.
The Oncologist
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Post-surgical ctDNA as a prognostic biomarker for relapse of resected cholangiocarcinoma

Marco Dal Molin, Dung Thi Le, Matthew Z. Guo, Mari Nakazawa, Kelly J. Lafaro, Marina Baretti, Daniel A. Laheru, Helen Catherine Wilbur, Richard Andrew Burkhart, Eric Scott Christenson, Christopher R. Shubert, Mark M. Yarchoan, Robert Anders, Linda Ye, William Burns, Nilofer Saba Azad, Thanh Nguyen, Jin He
article en

Abstract

BACKGROUND: ctDNA is increasingly used to detect minimal residual disease, however, its sensitivity varies by tumor type. Its utility in CCA remains incompletely defined. METHODS: In this single-institution retrospective study, we evaluated ctDNA using a commercial tumor-informed assay (Signatera), compared with CA19-9, for predicting relapse after surgical resection during postoperative (<90 days) and surveillance (≥90 days) windows. We assessed associations between ctDNA status and clinical features, including resection pathology and sites of radiographic relapse. RESULTS: Of 48 patients with CCA who underwent resection between 2020-2025, 26 (54.2%) experienced relapse (median follow-up 18.3 months). ctDNA positivity during both postoperative and surveillance windows was associated with worse median disease-free survival, whereas CA19-9 was not. During the postoperative window, ctDNA sensitivity was 41.7% and specificity was 85.7% for predicting disease relapse any time post-resection. During the surveillance window, sensitivity was 60.0% and specificity was 90.9%. Landmark analysis for relapse at 1-year for ctDNA collected prior to 90 days had a sensitivity of 83.3% and specificity of 90.0%. Among patients with detectable ctDNA who subsequently developed radiographic relapse, median lead time from first ctDNA positivity to relapse was 34 days (IQR 26-132 days), with a maximum lead time of 292 days. ctDNA performance was higher among patients without perineural or lymphovascular invasion and was most frequently positive in those who developed extrahepatic metastases (n = 10/13, 76.9%). CONCLUSIONS: ctDNA is a specific prognostic biomarker that outperforms CA19-9 for predicting relapse after CCA. However, negative ctDNA results should be interpreted cautiously given modest assay sensitivity.

The Oncologist
Johns Hopkins University (US), Johns Hopkins Medicine (US), Sidney Kimmel Comprehensive Cancer Center (US)
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon